3-Nitrophthalate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Nitrophthalate
• 化学式: C8H3NO6-2
• 分子量: 209.11
• InChiKey: KFIRODWJCYBBHY-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  126
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] PHTHALAZINES AS POTASSIUM ION CHANNEL INHIBITORS<br/>[FR] PHTHALAZINES SERVANT D'INHIBITEURS DES CANAUX IONIQUES POTASSIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014143608A1

  公开（公告）日：2014-09-18

  A compound of formula (I), wherein A, R1, R3, and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.

  一种具有化学式（I）的化合物，其中A、R1、R3和R24如本文所述。这些化合物可用作钾通道功能的抑制剂，并用于治疗和预防心律失常、IKur相关疾病以及其他由离子通道功能介导的疾病。
• Indeno [1,2-c]pyrazol-4-ones and their uses
  申请人：——

  公开号：US20010027195A1

  公开（公告）日：2001-10-04

  The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1 that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

  本发明涉及合成一种新类别的indeno[1,2-c]pyrazol-4-ones化合物，其化学式为(I):1，这些化合物是一类名为细胞周期依赖性激酶的酶的强效抑制剂，与催化亚基cdk1-9及其调节亚基cyclins A-H有关。本发明还提供了一种新颖的治疗癌症或其他增生性疾病的方法，即通过给予这些化合物中的一种或其药用可接受的盐形式的治疗有效剂量。另外，可以通过给予本发明化合物之一与一种或多种其他已知的抗癌或抗增生剂的治疗有效组合来治疗癌症或其他增生性疾病。
• AZA-PHENALENE-3-KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND ITS APPLICATION AS PARP INHIBITOR
  申请人：SUZHOU KANGRUN PHARMACEUTICALS INC.

  公开号：US20180134722A1

  公开（公告）日：2018-05-17

  Disclosed are an aza-phenalene-3-ketone derivative, a preparation method thereof and its application as a PARP inhibitor. The aza-phenalene-3-ketone derivative has the following structure: wherein R is hydrogen, methyl, ethyl, isopropyl, benzyl or 3-methyl-3-butenyl. The aza-phenalene-3-ketone derivative has very high activity for inhibiting PARP, thereby providing a good basis for new drug research of developing a nitrogen-doped phenalene-3-ketone compound as PARP inhibitor to treat cancer.

  揭示了一种氮杂苯并-3-酮衍生物，其制备方法及其作为PARP抑制剂的应用。该氮杂苯并-3-酮衍生物具有以下结构：其中R为氢、甲基、乙基、异丙基、苄基或3-甲基-3-丁烯基。该氮杂苯并-3-酮衍生物对于抑制PARP具有非常高的活性，从而为开发氮掺杂苯并-3-酮化合物作为PARP抑制剂用于治疗癌症的新药研究提供了良好的基础。
• PHTHALAZINES AS POTASSIUM ION CHANNEL INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140303168A1

  公开（公告）日：2014-10-09

  A compound of formula (I) wherein A, R 1 , R 3 , and R 24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I Kur -associated disorders, and other disorders mediated by ion channel function.

  化合物的公式为（I），其中A，R1，R3和R24的描述如下。这些化合物可用作钾通道功能的抑制剂，并用于治疗和预防心律失常，IKur相关疾病以及其他离子通道功能介导的疾病。
• Process for the regiospecific synthesis of anthracyclinone compounds such as daunomycinone
  申请人：THE UNIVERSITY OF KANSAS

  公开号：EP0063945A1

  公开（公告）日：1982-11-03

  A regiospecific synthesis for anthracyclinones asymmetric is disclosed. The synthesis is based upon a regiospecific bromination of the C-7 position of the a-tetralone which after transposing the keto group to the β-position and reaction with an organo-lithium compound is condensed with a phthalate ester.

  本发明公开了一种不对称蒽环类化合物的区域特异性合成方法。该合成基于 a-四氢萘酮 C-7 位的区域特异性溴化反应，在将酮基转位到 β 位并与有机锂化合物反应后，与邻苯二甲酸酯缩合。